Literature DB >> 35572859

Influence of body composition measures on chyle leak after oesophagectomy.

James M Halle-Smith1, Manjunath Siddaiah-Subramanya1, Abdulrahman Ghoneim1, Ahmed Almonib1, Benjamin H L Tan1.   

Abstract

Background: Chyle leak (CL) is an infrequent but potentially serious complication of oesophagectomy. Sarcopenia is an increasingly recognised prognostic factor in oesophageal cancer surgery. The aim of this study was to identify the influence of body composition measures on CL following oesophagectomy.
Methods: Patients who developed CL after oesophagectomy between January 2006-December 2020 were identified retrospectively from a prospectively maintained dataset. A control group of patients undergoing oesophagectomy, who did not experience chyle leak during the same time period, was also collected. Relationships between CL and demographics, operative factors and body composition measures were investigated as primary outcomes. Risk factors for severe CL were evaluated as a secondary outcome.
Results: There were 26 patients who developed a CL following an oesophagectomy. On univariate analysis, preoperative body mass index (BMI) (P=0.001), subcutaneous fat index (P=0.001) and total fat index (P=0.004) were significantly associated with CL. On multivariate analysis, a lower preoperative subcutaneous fat index was a significant independent predictor of CL (P=0.003). Sarcopenia, as an overall measure, was not found to be a significant predictor of developing CLs. No significant predictors of severe CL were identified. Conclusions: A reduced preoperative BMI and body fat composition are risk factors for CL after oesophagectomy. Sarcopenia does not predict either the occurrence or severity of CL. This presents potentially modifiable risk factors for CL after oesophagectomy and emphasises the importance of physiological and nutritional optimisation before oesophagectomy. 2022 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Chyle leak (CL); body mass index (BMI); oesophagectomy; sarcopenia

Year:  2022        PMID: 35572859      PMCID: PMC9096299          DOI: 10.21037/jtd-21-1580

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


Introduction

With a reported incidence between 1.1–3.8%, chyle leak (CL) is an infrequent but potentially serious complication of oesophagectomy (1-5). Whilst mild CL may be managed conservatively, surgical management is often required (5,6), for example in high output leaks (7). It is therefore desirable to identify any preoperative factors that increase the risk of CL after oesophagectomy, to improve individualised preoperative counselling and risk stratification. Preoperative nutritional status has been shown to be significantly related to risk of complications after oesophagectomy (8-10). Given that nutritional status can be accurately assessed using preoperative cross-sectional imaging (11), body composition measures such as sarcopenia are increasingly being used as preoperative risk assessment tools for major surgery such as oesophagectomy (12-15). However, the interaction between CL and body composition is not known. Therefore, the aim of this study was to identify the influence of body composition and related factors on CL following oesophagectomy. We present the following article in accordance with the STARD reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-21-1580/rc).

Methods

A prospectively collected and maintained departmental database of oesophageal cancer resections between January 2006–December 2020 was reviewed retrospectively to identify patients who developed CL after oesophageal cancer resection. A control group of patients who underwent oesophagectomy, who did not experience CL, for cancer during the same time period was also collected from the same departmental database to allow for investigation of risk factors. Oesophagectomy was performed in accordance with the operating surgeon’s expertise and case. If the thoracic duct is visualized intraoperatively it was ligated with ties or clips. Relationships between CL and demographics, operative factors and body composition measures were investigated as primary outcomes. Risk factors for severe CL, defined as need for reintervention or greater than 1 litre of output per day, were evaluated as a secondary outcome.

Sarcopenia and myosteatosis evaluation

Computed tomography (CT) scan has proven to be accurate for measuring human body composition (11). Regional muscle tissue was measured on CT scans performed on diagnosis as part of the staging process preoperatively. Preoperative CT scans, that were previously used in the staging process, were reviewed to evaluate body composition measures such as sarcopenia and myosteatosis. A transverse CT image from L3 was assessed from each scan. Images were analysed with SliceOmatic V4.3 software (Tomovision, Montreal, QB, Canada), which enables specific tissue demarcation using previously reported Hounsfield unit (HU) thresholds (11). Skeletal muscle is identified and quantified by HU thresholds of −29 to +150. Muscles in the L3 region encompass psoas, erector spinae, quadratus lumborum, transversus abdominus, external and internal obliques, and rectus abdominus. The following HU thresholds were used for adipose tissues: −190 to −30 for subcutaneous and intermuscular adipose tissues and −150 to −50 for visceral adipose tissues (16). Cross-sectional areas (cm2) were automatically computed by summing tissue pixels and multiplying by pixel surface area. Cross-sectional area of muscle and adipose tissue was normalized for stature (cm2/m2) as reported elsewhere (17), and this value is referred to as the L3 (Skeletal Muscle Index) SMI. Cut-offs for sarcopenia were based on a CT-based study in patients with solid tumours using optimal stratification, a statistical method similar to receiver operator curve analysis, to solve specific threshold values for L3 SMI in relation to an outcome (death) (L3 SMI: ≤41 cm2/m2 for women and ≤53 cm2/m2 for men with BMI ≥25 and ≤43 cm2/m2 in patients with BMI <25) (16). Muscle attenuation indirectly measures fat infiltration in muscles. Mean muscle attenuation in HU was reported for the entire muscle area at the third lumbar vertebra. We also, used previous cut-off values for muscle attenuation previously associated with mortality, specifically <41HU in patients with a BMI up to 24.9, and <33 in those with a BMI ≥25 (16). Sarcopenic obesity was defined as those patients with concurrent sarcopenia and overweight or obesity (BMI >25 kg/m2).

Statistical analyses

Comparisons were initially made between the CL and no CL groups. Univariate analyses were performed using Chi-Squared test for categorical variables and Mann-Whitney U test for continuous variables. Multivariate analyses were then performed, to identify independent predictors of CL, using multivariable cox regression modelling with a forward stepwise approach. Receiver operating characteristic (ROC) curves were then used to quantify the relationship of body composition measures to the development of CL. All analyses were performed using IBM SPSS Statistics 26 (IBM Corp. Armonk, NY, USA), with P<0.05 deemed to be indicative of statistical significance.

Institutional approval

This was a retrospective human study so individual patient consent was not required for this study. Institutional approval for this study was acquired from the local Clinical Audit Registration and Management System (No. CARMS-16870). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Results

There were 26 patients who developed a CL following an oesophagectomy during the study period and 60 patients were included in the control group (). Age and gender were similar between the CL and no CL cohorts whilst preoperative body mass index (BMI) (P=0.001), subcutaneous fat index (P=0.001) and total fat index (P=0.004) were significantly associated with CL ().
Table 1

Baseline characteristics of chyle leak and no chyle leak cohort

FactorChyle leak (n=26)No chyle leak (n=60)P
Age71 [62–76]66 [59–70]0.085
Gender, male22 [85]48 [80]0.767
BMI24 [22–27]27 [25–32]0.001
Neoadjuvant chemotherapy20 [77]49 [82]0.769

Given as n (%) or median (Q1–Q3). Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). BMI, body mass index.

Table 2

Relationship between body composition measures and chyle leak after oesophagectomy

FactorChyle leak (n=26)No chyle leak (n=60)P
Preoperative sarcopenia10 [46]36 [60]0.316
Preoperative myosteatosis13 [59]33 [56]1
Preoperative BMI24 [22–27]27 [25–32]0.001
Preoperative subcutaneous fat index34 [25–47]71 [42–103]0.001
Preoperative visceral fat index54 [39–92]68 [48–96]0.135
Preoperative total fat index95 [71–136]148 [103–184]0.004
Preoperative muscle HU36 [32–41]34 [29–38]0.072

Given as n (%) or median (Q1–Q3). Fat indices calculated by diving fat area by height in metres squared. (cross-sectional area of skeletal muscle was normalized for stature (cm2/m2) as reported elsewhere (17). Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). BMI, body mass index; HU, Hounsfield units.

Given as n (%) or median (Q1–Q3). Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). BMI, body mass index. Given as n (%) or median (Q1–Q3). Fat indices calculated by diving fat area by height in metres squared. (cross-sectional area of skeletal muscle was normalized for stature (cm2/m2) as reported elsewhere (17). Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). BMI, body mass index; HU, Hounsfield units. On multivariate analysis, a lower preoperative subcutaneous fat index was a significant independent predictor of CL (P=0.003). Sarcopenia was not found to be a significant predictor of developing CL ().
Table 3

Multivariate analysis to determine independent predictors of chyle leak after oesophagectomy

FactorOdds ratio (95% CI)P
Preoperative BMI0.214
Preoperative subcutaneous fat index1.026 (1.009–1.043)0.003
Preoperative total fat index0.925

Multivariate analyses performed using multivariable cox regression modelling with forwards stepwise approach. CI, confidence interval; BMI, body mass index.

Multivariate analyses performed using multivariable cox regression modelling with forwards stepwise approach. CI, confidence interval; BMI, body mass index. The relationship between body composition measures and CL were further investigated with ROC curves. Decreasing preoperative subcutaneous fat index [area under the receiver operating characteristic curve (AUROC) 0.744, P=0.001] and BMI (AUROC 0.728, P=0.001) were significantly associated with CL ().
Figure 1

ROC curves generated using SPSS Statistics 26 (IBM Corp. Armonk, NY, USA). The AUROC for A =0.744 (P=0.001) and B =0.728 (P=0.001). (A) ROC curve demonstrating the relationship between subcutaneous fat index and chyle leak after oesophagectomy. (B) ROC curve demonstrating the relationship between body mass index and chyle leak after oesophagectomy. ROC, receiver operating characteristic; AUROC, area under the receiver operating characteristic curve.

ROC curves generated using SPSS Statistics 26 (IBM Corp. Armonk, NY, USA). The AUROC for A =0.744 (P=0.001) and B =0.728 (P=0.001). (A) ROC curve demonstrating the relationship between subcutaneous fat index and chyle leak after oesophagectomy. (B) ROC curve demonstrating the relationship between body mass index and chyle leak after oesophagectomy. ROC, receiver operating characteristic; AUROC, area under the receiver operating characteristic curve. There were 10 (38%) patients who developed a severe CL but no significant predictors of severe CL were identified ().
Table 4

Factors affecting severity of chyle leak

FactorMild chyle leak (n=16)Severe chyle leak (n=10)P
Demographics
    Age69 [63–77]73 [62–73]0.816
    Male14 [88]8 [80]0.625
    BMI23 [22–25]25 [23–28]0.310
Oesophagectomy type0.723
   Open3 [19]3 [30]
   Hybrid6 [38]4 [40]
   MIO7 [44]3 [30]
Neoadjuvant Therapy
   Neoadjuvant Chemotherapy14 [88]6 [60]0.163
   Neoadjuvant Chemoradiotherapy0 (0)2 [20]0.138
Preoperative Bloods
   Albumin41 [35–46]44 [37–46]0.484
   CRP5 [3–7]8 [3–14]0.464
   NLR3.0 (2.6–3.7)2.7 (2.1–4.2)0.938
Preoperative sarcopenia5 [31]5 [50]0.378
Preoperative myosteatosis8 [50]5 [50]1.000
   Preoperative subcutaneous fat index34 [25–38]39 [26–58]0.616
   Preoperative visceral fat index54 [39–73]68 [36–100]0.714
   Preoperative total fat index95 [66–136]103 [75–139]0.570
   Preoperative Mus HU35 [33–41]38 [32–41]0.920
   Preoperative SMI49 [44–53]43 [40–46]0.145

Given as n (%) or median (Q1-Q3). Fat indices calculated by diving fat area by height in metres squared. HU, Hounsfield units. SMI, skeletal muscle index [cross-sectional area of skeletal muscle was normalized for stature (cm2/m2) as reported elsewhere (17)]. Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). MIO, minimally invasive oesophagectomy; BMI, body mass index; NLR, neutrophil:lymphocyte ratio; CRP, C-reactive protein.

Given as n (%) or median (Q1-Q3). Fat indices calculated by diving fat area by height in metres squared. HU, Hounsfield units. SMI, skeletal muscle index [cross-sectional area of skeletal muscle was normalized for stature (cm2/m2) as reported elsewhere (17)]. Univariate analyses performed using Chi-Squared test (categorical variables) and Mann-Whitney U test (continuous variables). MIO, minimally invasive oesophagectomy; BMI, body mass index; NLR, neutrophil:lymphocyte ratio; CRP, C-reactive protein.

Discussion

This retrospective descriptive study sought to investigate the aetiology of CL after oesophagectomy using body composition measures. The main finding is that a reduced preoperative body fat composition is a risk factor for CL after oesophagectomy. This is similar to previous studies which have reported a reduced incidence of CL after oesophagectomy amongst those with a higher BMI (18-21). CL seems to be anomalous in this regard, as other complications after oesophagectomy such as anastomotic leakage have been shown to be increased amongst those with a higher BMI (20,22-24). Sarcopenia did not influence either the occurrence or severity of CL. Given that sarcopenia has frequently been shown to increase prevalence of complications after oesophagectomy (21,25), it was surprising that was not related to the prevalence of CL in this study. Rather, it seems that body fat is the most important factor influencing CL, opposed to muscle mass. Given this important finding and the fact that preoperative CT scans are readily available, clinicians could certainly consider routine preoperative measurement of body fat indices as this may allow some individualised risk stratification. The mechanism for increased CL rate amongst those with a lower BMI and in this study, specifically a reduced body fat composition, is unclear and previous cohort studies and meta-analyses have also struggled to explain this finding (22). Reviewing the physiology, it is possible to suggest some potential causes. For instance, it is known that fasting can dramatically reduce flow through the thoracic duct, down to 1 mL/minute, which is in contrast to the physiological norm of approximately 200 mL/minute with normal diet (26-28). A reduction in flow could make the thoracic duct and its tributaries more difficult to identify intraoperatively, leading to an increase in iatrogenic injury. Furthermore, it is known that lymph flow is increased with hypertension (26,29). This then may explain why those with a higher BMI, who are more likely to be hypertensive, have a lower incidence of CL. Previously published evidence indicates that nutritional status may not only be important preoperatively, but also play a vital role in patients’ recovery from CL (30-32). It is likely that this is related to both the loss of plasma proteins, such as albumin, and immune cells, such as lymphocytes. Combined, these will lead to impairment of the patient’s tissue healing and immune function. This emphasises the importance of physiological and nutritional optimisation before oesophagectomy to both reduce the likelihood of CL and to promote its recovery in the event it does occur. Limitations of this study include its retrospective nature and the fact that CL is a relatively uncommon complication, so the number of patients are small and cases that are included in this study are spread over a large time period of time. Furthermore, in this study sarcopenia was assessed purely on a radiological basis, whereas the European Working Group on Sarcopenia in Older People (EWGSOP) does recommend the use of both low muscle mass and low muscle function to diagnose sarcopenia (33). In this study muscle function was not used but this is certainly an area of development for future studies. The knowledge that reduced preoperative body fat increases the risk of CL presents a potentially modifiable risk factor for CL after oesophagectomy. Preoperative nutritional and physical optimisation could help to reduce CL rates after oesophagectomy. The article’s supplementary files as
  33 in total

1.  Chylothorax complicating esophagectomy for cancer: a plea for early thoracic duct ligation.

Authors:  S Merigliano; D Molena; A Ruol; G Zaninotto; M Cagol; S Scappin; E Ancona
Journal:  J Thorac Cardiovasc Surg       Date:  2000-03       Impact factor: 5.209

2.  Chylothorax.

Authors:  Askari Pembe Townshend; William Speake; Adam Brooks
Journal:  Emerg Med J       Date:  2007-02       Impact factor: 2.740

3.  Spontaneous healing of retroperitoneal chylous leakage following anterior lumbar spinal surgery: a case report and literature review.

Authors:  I-Chang Su; Chang-Mu Chen
Journal:  Eur Spine J       Date:  2007-02-02       Impact factor: 3.134

4.  Chronic transvascular fluid flux and lymph flow during volume-loading hypertension.

Authors:  J Valenzuela-Rendon; R D Manning
Journal:  Am J Physiol       Date:  1990-05

5.  Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Laura A Healy; Aoife M Ryan; Bussa Gopinath; Suzanne Rowley; Patrick J Byrne; John V Reynolds
Journal:  J Thorac Cardiovasc Surg       Date:  2007-11       Impact factor: 5.209

6.  Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer.

Authors:  Tatsuto Nishigori; Hiroshi Okabe; Eiji Tanaka; Shigeru Tsunoda; Shigeo Hisamori; Yoshiharu Sakai
Journal:  J Surg Oncol       Date:  2016-03-03       Impact factor: 3.454

7.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.

Authors:  Marina Mourtzakis; Carla M M Prado; Jessica R Lieffers; Tony Reiman; Linda J McCargar; Vickie E Baracos
Journal:  Appl Physiol Nutr Metab       Date:  2008-10       Impact factor: 2.665

8.  Sarcopenia: revised European consensus on definition and diagnosis.

Authors:  Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni
Journal:  Age Ageing       Date:  2019-01-01       Impact factor: 10.668

9.  CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma.

Authors:  Uli Fehrenbach; Tilo Wuensch; Pia Gabriel; Laura Segger; Takeru Yamaguchi; Timo Alexander Auer; Nick Lasse Beetz; Christian Denecke; Dino Kröll; Jonas Raakow; Sebastian Knitter; Sascha Chopra; Peter Thuss-Patience; Johann Pratschke; Bernd Hamm; Matthias Biebl; Dominik Geisel
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

10.  Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.

Authors:  R B den Boer; K I Jones; S Ash; G I van Boxel; R S Gillies; T O'Donnell; J P Ruurda; B Sgromo; M A Silva; N D Maynard
Journal:  BJS Open       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.